NCT01798446View on ClinicalTrials.gov

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2016

Conditions
Renal Cell CarcinomaNonclear CellTemsirolimus Resistance
Interventions
DRUG

Axitinib

Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.

Trial Locations (1)

110744

Seou National University Hospital, Seoul

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Seoul National University Hospital

OTHER